natgillin/translations-raw huggingface dataset:
The process according to claim 1, characterized in that the minerals are selected from the group comprising natural minerals, synthetic minerals, fillers or pigments such as dry and wet ground natural calcium carbonate such as chalk, limestone, calcite, marble and dolomite; precipitated calcium carbonate in its aragonitic, calcitic and vateritic form; calcium sulfate; quartz; attapulgite; clays such as kaolin, kaolinitic clay, calcined kaolinitic clay and montmorillonite; mica; talc; diatomaceous earth; finely divided silica; aluminium oxide; aluminium hydroxide; silicates such as aluminium silicate; iron oxide; titanium dioxide; pumice; sepiolite, and mixtures thereof as well as composite materials comprising one or more of the afore-mentioned substances, e.g. 
Postupak prema patentnom zahtjevu 1, naznačen time da su minerali izabrani iz skupine koja sadrži prirodne minerale, sintetičke minerale, punila ili pigmente kao što su prirodni kalcij karbonat suhe ili mokre zemlje, poput krede, vapnenca, kalcita, mramora i dolomita; istaloženi kalcij karbonat u njegovoj aragonitskom, kalcitskom ili vateritskom obliku; kalcij sulfat; kvare; atapulgit; gline poput kaolina, kaolinitske gline, kalcinirane kaolinitske gline i montmorilonita; tinjac; talk; dijatomejsku zemlju; fino razdvojenu siliku; aluminij oksid; aluminij hidroksid; silikate poput aluminij silikata; željezo oksid; titanij dioksid; plavac; sepiolit, te njihove smjese kao i kompozitne materijale koji sadrže jednu ili više od prethodno navedenih tvari, npr.
The antibody of Claim 1 or Claim 2, wherein the antibody specifically depletes IgE-producing B-cells when a therapeutically effective amount is administered in vivo to a mammal and optionally reduces total serum IgE or reduces free serum IgE; wherein optionally the IgE is allergen-specific. 
Protutijelo prema zahtjevu 1 ili zahtjevu 2, naznačeno time, da protutijelo specifično iscrpljuje proizvodnju B-stanica koje proizvode IgE, kada se terapeutski djelotvorna količina primjenjuje na sisavcu in vivo i po želji se smanjuje ukupni IgE-serum ili se smanuje slobodni IgE-serum; pri čemu je IgE po potrebi alergenski specifičan.
The antibody of any one the preceding claims that specifically binds to the same epitope as one bound by an antibody selected from the group consisting of: 47H4 (ATTC Dep. 
Protutijelo prema jednom od prethodnih zahtjeva, naznačeno time, da se specifično veže na isti epitop koji je spojen pomoću protutijela odabranog iz skupine koju čine: 47H4 (ATTC Dep.
PTA-8262), 47H4v5 comprising a variable light chain having the amino acid sequence shown as SEQ ID NO:31 (Fig. 
PTA-8262), 47H4v5 koji sadrži amino kiselinsku sekvencu varijabilnog slabog lanca, prikazanu u SEQ ID NO:31 (Sl.
6F), 7A6v1 comprising a variable light chain having the amino acid sequence shown as SEQ ID NO:28 (Fig. 
6F), 7A6v1 koji sadrži amino kiselinsku sekvencu varijabilnog slabog lanca, prikazanu u SEQ ID NO:28 (Sl.
6E), and 26A11 v6 comprising a variable light chain having the amino acid sequence shown as SEQ ID NO:24 (Fig. 
6E), i 26A11v6 koji sadrži amino kiselinsku sekvencu varijabilnog slabog lanca, prikazanu u SEQ ID NO:24 (Sl.
The antibody of any one the preceding claims that binds with a Scatchard binding affinity that is equivalent to that of the murine anti-IgE/M1' antibody 47H4 (ATTC Dep. 
Protutijelo prema jednom od prethodnih zahtjeva, naznačeno time, da se spaja sa Scatchard-afinitetom vezivanja koji odgovara onom od mišjeg anti-IgE/M1’ protutijela 47H4 (ATTC Dep.
The antibody of any one the preceding claims that specifically binds to an M1' segment of IgE with a Scatchard binding affinity that is equivalent to that of humanized anti-IgE/M1' antibody 47H4v5 comprising a variable light chain having the amino acid sequence shown as SEQ ID NO:31 (Fig. 
Protutijelo prema jednom od prethodnih zahtjeva, naznačeno time, da se specifično spaja na M1’ segment od IgE sa Scatchard-afinitetom vezivanja, koji odgovara onom od humaniziranog anti-IgE/M1’ protutijela 47H4v5 koje sadrži amino kiselinsku sekvencu varijabilnog slabog lanca prikazanu u SEQ ID NO:31 (Sl.
The antibody of any one the preceding claims comprising the heavy chain and light chain HVRs of an antibody or antigen-binding fragment thereof selected from the group consisting of: 26A11 as shown in SEQ ID NO: 21 (Fig. 
Protutijelo prema jednom od prethodnih zahtjeva, naznačeno time, da sadrži HVRs jakog lanca i slabog lanca od protutijela ili njegovog fragmenta koje/i veže antigen, odabrane iz skupine koju čine: 26A11 prikazano u SEQ ID NO:21 (Sl.
6F), and preferably comprising the heavy and light chain HVRs or an antibody or antigen-binding fragment thereof of 47H4v1-6 as shown in SEQ ID NOs: 30 and 31 (Fig. 
6F), te po želji sadrži HVRs jakog i slabog lanca ili protutijelo ili njegov fragment, koje/i veže antigen od 47H4v1-6 kako je prikazano u SEQ ID NO:30 i SEQ ID NO:31 (Sl.
The composition of Claim 13 further comprising one or more drugs selected from the group consisting of: anti-IgE antibody, antihistamine, bronchodilator, glucocorticoid, NSAID, TNF-antagonist, integrin antagonist, immunosuppressive agent, IL-4 antagonist, IL-13 antagonist, dual IL-4/IL-13 antagonist, DMARD, antibody that binds to a B-cell surface marker and BAFF antagonist. 
Sastav prema zahtjevu 13, naznačen time, da nadalje obuhvaća jedan ili više lijekova odabranih iz skupine koju čine: protutijelo anti-IgE, antihistamin, bronhodilator, glukokortikoid, NSAID, TNF-antagonist, integrinski antagonist, imunosupresivno sredstvo, IL-4-antagonist, IL-13-antagonist, dvojni IL-4/IL-13-antagonist, DMARD, protutijelo koje se veže na površinski marker B-stanice i BAFF-antagonist.
An isolated nucleic that encodes an antibody or antigen-binding fragment thereof comprising the heavy and light chain HVRs of an apoptotic anti-IgE/M1' antibody or antigen-binding fragment thereof selected from the group consisting of: 26A11 as shown in SEQ ID NO: 21 (Fig. 
Izolirana nukleinska kiselina, naznačena time, da kodira protutijelo ili njegov fragment koji veže antigen, pri čemu sadrži HVRs jakog i slabog lanca od apoptotičkog anti-IgE/M1’ protutijela ili njegovog fragmenta koji veže antigen, odabrane iz skupine koju čine: 26A11 prikazano u SEQ ID NO:21 (Sl.
The nucleic acid of Claim 15, further comprising nucleic acid encoding the variable regions of the heavy and light chains of the antibody sequence selected from the group consisting of: 26A11 as shown in SEQ ID NO: 21 (Fig. 
Nukleinska kiselina prema zahtjevu 15, naznačena time, da nadalje obuhvaća nukleinsku kiselinu koja kodira varijabilna područja jakog i slabog lanca od sekvence protutijela odabrane iz skupine koju čine: 26A11 prikazano u SEQ ID NO:21 (Sl.
The nucleic acid of Claim 16, wherein the encoded antibody is afucosylated. 
Nukleinska kiselina prema zahtjevu 16, naznačena time, da kodirano protutijelo je afukosilirano.
An article of manufacture enclosing the composition of Claim 13 or Claim 14 and a package insert indicating use for the treatment of an IgE-mediated disorder. 
Predmet proizvodnje, naznačen time, da obuhvaća sastav prema zahtjevu 13 ili zahtjevu 14 i umetak u pakiranju koji navodi upute za uporabu u liječenju poremećaja posredovanih s IgE.
An antibody of any one of claims 1 to 11 for use in a method for specifically depleting IgE-producing B-cells, the method comprising administering to a mammal a therapeutically effective amount of said anti-IgE/M1' antibody, and optionally wherein the antibody has ADCC activity. 
Protutijelo prema bilo kojem zahtjevu od 1 do 11, naznačeno time, da se upotrebljava u postupku za specifično iscrpljivanje B-stanica koje proizvode IgE, gdje postupak obuhvaća primjenu terapeutski djelotvorne količine spomenutog anti-IgE/M1’ protutijela na sisavcu, pri čemu protutijelo po želji ima ADCC-djelotvornost.
the antibody is for administration in combination with a therapeutically effective amount of at least one drug selected from the group consisting of: anti-IgE antibody, antihistamine, bronchodilator, glucocorticoid, NSAID, decongestant, cough suppressant, analgesic, TNF-antagonist, integrin antagonist, immunosuppressive agent, IL-4 antagonist, IL-13 antagonist, dual IL-4/IL-13 antagonist, DMARD, antibody that binds to a B-cell surface marker and BAFF antagonist; and/or 
je protutijelo za primjenu u kombinaciji s terapeutski djelotvornom količinom barem jednog lijeka odabranog iz skupine koju čine: protutijelo anti-IgE, antihistamin, bronhodilator, glukokortikoid, NSAID, dekongestant, sredstvo za obuzdavanje kašlja, analgetik, TNF-antagonist, integrinski antagonist, imunosupresivno sredstvo, IL-4-antagonist, IL-13-antagonist, dvojni IL-4/IL-13-antagonist, DMARD, protutijelo koje se veže na površinski marker B-stanice i BAFF-antagonist; i/ili
the antibody is for administration in a combined treatment regimen which comprises administering a therapeutically effective amount of said anti-IgE/M1' antibody prior to, simultaneous with or after the administration of a known method of treatment for allergic disorders. 
je protutijelo za primjenu u kombiniranom režimu liječenja koje obuhvaća primjenu terapeutski djelotvorne količine spomenutog anti-IgE/M1’ protutijela, prije, istovremeno ili nakon primjene poznatog postupka liječenja za alergijske poremećaje.
the known treatment for allergic disorder comprises the administration of an anti-IgE antibody antihistamine, a bronchodilator, a glucocorticoid, a non-steroidal anti-inflammatory drug, an immunosuppressant, a IL-4 antagonist, a IL-13 antagonist, a dual IL-4/IL-13 antagonist, a decongestant, a cough suppressant or an analgesic; or 
poznati postupak liječenja alergijskih poremećaja obuhvaća primjenu protutijela anti-IgE, antihistamina, bronhodilatora, glukokortikoida, nesteroidnog protuupalnog lijeka, imunosupresanta, IL-4-antagonista, IL-13-antagonista, dvojnog IL-4/IL-13-antagonista, sredstva protiv zagušenja, sredstva za obuzdavanje kašlja ili analgetika; ili
the known treatment for allergic disorder comprises a treatment regimen of allergen densitization. 
poznato liječenje za alergijske poremećaje obuhvaća režim liječenja alergijskom desenzibilizacijom.
The antibody for use in a method of treatment of any one of Claims 24 to 27, wherein the method is for preventing or reducing allergen-induced IgE production. 
Protutijelo za uporabu prema zahtjevima od 24 do 27, naznačeno time, da se upotrebljava u postupku za sprečavanje ili smanjivanje proizvodnje alergijski induciranog IgE.
the IgE-mediated disorder is selected from the group consisting of: allergic rhinitis, allergic asthma, non-allergic asthma, atopic dermatitis, allergic gastroenteropathy, anaphylaxis., urticaria, food allergies, allergic bronchopulmonary aspergillosis, parasitic diseases, interstitial cystitis, hyper-IgE syndrome, ataxia-telangiectasia, Wiskott-Aldrich syndrome, athymic lymphoplasia, IgE myeloma, graft-versus-host reaction and allergic purpura; and/or 
je poremećaj posredovan s IgE odabran iz skupine koju čine: alergijski rinitis, alergijska astma, nealergijska astma, atopički dermatitis, alergijska gastroenteropatija, anafilaksa, urtikarija, alergije na hranu, alergijska bronhopulmonarna aspergiloza, parazitne bolesti, intersticijski cistitis, hiper-IgE-sindrom, ataxia-telangiectasia, sindrom Wiskott-Aldrich, atimijska limfoplazija, IgE mijelom, reakcija usatka protiv stanice domaćina i alergijska purpura; i/ili
the antibody is for administration in combination with a therapeutically effective amount of at least one drug selected from the group consisting of: anti-IgE antibody, antihistamine, bronchodilator, glucocorticoid, NSAID, decongestant, cough suppressant, analgesic, TNF-antagonist, integrin antagonist, immunosuppressive agent, IL-4 antagonist, IL-13 antagonist, dual IL-4/IL-13 antagonist, DMARD, antibody that binds to a B-cell surface marker and BAFF antagonist. 
je protutijelo za primjenu u kombinaciji s terapeutski djelotvornom količinom barem jednog lijeka odabranog iz skupine koju čine: protutijelo anti-IgE, antihistamin, bronhodilator, glukokortikoid, NSAID, dekongestant, sredstvo za obuzdavanje kašlja, analgetik, TNF-antagonist, integrinski antagonist, imunosupresivno sredstvo, IL-4- antagonist, IL-13-antagonist, dvojni IL-4/IL-13-antagonist, DMARD, protutijelo koje se veže na površinski marker B-stanice i BAFF-antagonist.
A transgenic animal that expresses the human M1' segment of IgE which comprises residues 317 to 351 of SEQ ID NO:1. 
Transgenska životinja, naznačena time, da izražava humani segment M1’ od IgE, koji sadrži ostatke od 317 do 351 iz SEQ ID NO:1.
A precipitation stable aqueous pharmaceutical composition which consists essentially of from 0.4% w/v to 1% w/v of a salt of deoxycholic acid and a pharmaceutically acceptable excipient, and wherein said composition is maintained at a pH from 8.2 to 8.5. 
Taložno stabilan vodeni farmaceutski pripravak, naznačen time što se uglavnom sastoji od 0,4% tež./vol. Do 1% tež./vol. soli deoksikolne kiseline i farmaceutski prihvatljive pomoćne tvari, te što se pH navedenog pripravka održava na 8,2 do 8,5.
The pharmaceutical composition according to claim 20, further comprising an additional agent selected from a mucolytic agent, a bronchodilator, an antibiotic, an anti-infective agent, an anti-inflammatory agent, a CFTR modulator other than a compound of Formula (I), or a nutritional agent. 
Farmaceutski pripravak prema zahtjevu 20, naznačen time da dodatno sadrži dodatno sredstvo koje je odabrano od mukolitičkog sredstva, bronhodilatora, antibiotika, anti-infektivnog sredstva, protuupalnog sredstva, CFTR modulatora koji je različit od spoja sa formulom (I), ili prehrambenog sredstva.
The compound for use according to claim 23, wherein said disease is cystic fibrosis. 
Spoj za uporabu prema zahtjevu 23, naznačen time da je navedena bolest cistična fibroza.
The compound for use according to claim 23, wherein said disease is associated with reduced CFTR function due to mutations in the gene encoding CFTR or environmental factors, wherein the disease is cystic fibrosis, chronic bronchitis, recurrent bronchitis, acute bronchitis, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), female infertility caused by congenital absence of the uterus and vagina (CAUV), idiopathic chronic pancreatitis (ICP), idiopathic recurrent pancreatitis, idiopathic acute pancreatitis, chronic rhinosinusitis, primary sclerosing cholangitis, allergic bronchopulmonary aspergillosis, diabetes, dry eye, constipation, allergic bronchopulmonary aspergillosis (ABPA), bone diseases, or asthma. 
Spoj za uporabu prema zahtjevu 23, naznačen time da je navedena bolest povezana sa smanjenom funkcijom CFTR zbog mutacija u genu koji kodira CFTR ili zbog faktora okoline, pri čemu je bolest cistična fibroza, kronični bronhitis, rekurentni bronhitis, akutni bronhitis, muška neplodnost uzrokovana sa urođenom obostranom agenezijom duktus deferensa (CBAVD), ženska neplodnost uzrokovana sa urođenim nedostatkom uterusa i vagine (CAUV), idiopatski kronični pankreatitis (ICP), idiopatski rekurentni pankreatitis, idiopatski akutni pankreatitis, kronični rinosinusitis, primarni sklerozni kolangitis, alergijska bronhopulmonarna aspergiloza, dijabetes, sindrom suhog oka, konstipacija, alergijska bronhopulmonalna aspergiloza (ABPA), bolesti kostiju, ili astma.
The compound for use of claim 23, wherein said disease is associated with normal CFTR function. 
Spoj za uporabu prema zahtjevu 23, naznačen time da je navedena bolest povezana s normalnom funkcijom CFTR.
The compound for use of claim 26, wherein the disease is chronic obstructive pulmonary disease (COPD), chronic bronchitis, recurrent bronchitis, acute bronchitis, rhinosinusitis, constipation, chronic pancreatitis, recurrent pancreatitis, and acute pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, liver disease, hereditary emphysema, gallstones, gastro-esophageal reflux disease, gastrointestinal malignancies, inflammatory bowel disease, constipation, diabetes, arthritis, osteoporosis, or osteopenia. 
Spoj za uporabu prema zahtjevu 26, naznačen time da je bolest kronična opstruktivna plućna bolest (KOPB), kronični bronhitis, rekurentni bronhitis, akutni bronhitis, rinosinusitis, konstipacija, kronični pankreatitis, rekurentni pankreatitis, te akutni pankreatitis, insuficijencija pankreasa, muška neplodnost uzrokovana sa urođenom obostranom agenezijom duktus deferensa (CBAVD), blaga bolest pluća, idiopatski pankreatitis, bolest jetre, nasljedni emfizem, žučni kamenci, gastro-ezofagealna refluksna bolest, gastrointestinalne maligne bolesti, upalna bolest crijeva, konstipacija, dijabetes, artritis, osteoporoza, ili osteopenija.
contacting an additional compound with the biological sample; 
kontakt dodatnog spoja s biološkim uzorkom;
measuring the activity of said CFTR or a fragment thereof in the presence of said additional compound, and 
mjerenje aktivnosti navedenog CFTR ili njegovog fragmenta u prisutnosti navedenog dodatnog spoja, te
The process of claim 33 further comprising a deprotection reaction when ring A is wherein Ra is a silyl protecting group, to generate a compound of Formula (I), wherein ring A is; 
Postupak prema zahtjevu 33 naznačen time da dodatno sadrži reakciju deprotekcije kada prsten A je [image] naznačen time da Ra je silil zaštitna skupina, da de dobije spoj sa formulom (I), pri čemu prsten A je; [image]
A compound of Formula (IA): or pharmaceutically acceptable salts thereof, wherein: 
Spoj sa formulom (IA): [image] ili njegove farmaceutski prihvatljive soli, naznačen time da:
ring A is selected from wherein 
prsten A je odabran od [image] pri čemu
is selected from the group consisting of F, Cl, Br, I, CH2Y, CHY2 and CY3, wherein Y is a halogen atom; and and R10 together with the carbon atom to which they are attached form an C3-6-cycloalkyl or C3-6- heterocyclyl, preferably a nitrogen-containing heterocyclyl; 
je odabran iz grupe koja se sastoji od F, Cl, Br, I, CH2Y, CHY2 i CY3, gdje je Y atom halogena; i R9 i R10 zajedno s atomom ugljika za koji su povezani tvore C3-6-cikloalkil ili C3-6-heterociklil, poželjno heterociklil koji sadrži dušik;
Compound according to any of claims 1-3, wherein R9 and R10 together with the carbon atom to which they are attached form an piperidinyl or piperazinyl, preferably an piperidinyl. 
Tvar u skladu s bilo kojim od patentnih zahtjeva 1-3, pri čemu R9 i R10 zajedno s atomom ugljika za kojeg su vezani tvore piperidinil ili piperazinil, poželjno piperidinil.
Compound according to any of claims 1-4, wherein R9 and R10 together with the carbon atom to which they are attached form an nitrogen-containing heteroaryl or heterocyclyl wherein the nitrogen atom is separated by two carbon atoms from the carbon atom to which R9 and R10 are attached. 
Tvar u skladu s bilo kojim od patentnih zahtjeva 1-4, pri čemu R9 i R10 zajedno s atomom ugljika za kojeg su vezani tvore heteroaril ili heterociklil koji sadrži dušik gdje je atom dušika odvojen dvjema atomima ugljika od atoma ugljika za koji su R9 i R10 vezani.
is selected from the group consisting of F, Cl, Br, I, CH2Y, CHY2 and CY3, wherein Y is a halogen atom; and 
je odabran iz grupe koja se sastoji od F, Cl, Br, I, CH2Y, CHY2 i CY3, gdje je Y atom halogena; i
A pharmaceutical composition comprising a compound according to any of claims 1-6 and at least one pharmaceutically acceptable carrier or exipient. 
Farmaceutski sastav sadrži tvar u skladu s bilo kojim od patentnih zahtjeva 1-6 i najmanje jedan farmaceutski prihvatljivi nosač ili ekscipijens.
A pharmaceutical composition according to claim 13, comprising a clinically relevant amount of the compound according to any of claims 1-6. 
Farmaceutski sastav u skladu s patentnim zahtjevom 13, sadrži klinički značajnu količinu tvari u skladu s bilo kojim od patentnih zahtjeva 1-6.
A process for removal of carbon dioxide from a feed gas comprising the steps of: 
Postupak za odstranjivanje ugljičnog dioksida iz napajajućeg plina koji sadrži korake:
cooling the gas obtained in step b, 
hlađenje plina dobijenog u koraku b,
cooling the liquid of absorbing agent obtained in step b, 
hlađenje tekućine apsorbenta dobijenog u koraku b,
absorbing carbon dioxide from the gas obtained in step d by means of the absorbing agent obtained in step e, by which the gas is separated into a gas, which may be disposed of, and a liquid of absorbing agent containing carbon dioxide, and 
apsorbiranje ugljičnog dioksida iz plina dobijenog u koraku d pomoću apsorbenta dobijenog u koraku e, čime se plin razdvaja na plin, koji može biti ispušten, i tekućinu apsorbenta koja sadrži ugljični dioksid, i
increasing the temperature and/or reducing the pressure of the liquid obtained in step f before recycling it to the stripper column. 
povećanje temperature i/ili smanjenje tlaka tekućine dobijene u koraku f prije njenog recikliranja u rektifikacijskoj koloni.
The process according to claims 1 or 2, wherein the feed gas originates from hydrogen plants upstream or downstream PSA units or from power plants. 
Postupak prema zahtjevima 1 ili 2, pri čemu napajajući plin potječe iz vodikovih postrojenja uzvodno ili nizvodno od PSA jedinica ili elektrana.
The process according to any of the claims 1 to 3, wherein the liquid obtained in step d is used as a cooling agent for the process by expansion and re-evaporation. 
Postupak prema bilo kojem od zahtjeva 1 do 3, pri čemu se tekućina dobijena u koraku d koristi kao rashladno sredstvo za postupak ekspanzijom i ponovnim isparavanjem.
The process according to any of the claims 1 to 9, wherein an intermediate cooling/separating step is incorporated between the steps b and c, in which the gas obtained in step b is firstly cooled, whereby part of the gas is condensed, and then separated into a carbon dioxide rich gas, which is subsequently cooled in step c, and a liquid comprising absorbing agent and carbon dioxide, which is recycled to the stripper column after increasing the temperature and/or reducing the pressure. 
Postupak prema bilo kojem od zahtjeva 1 do 9, pri čemu je između koraka b i c uključen međukorak hlađenja/razdvajanja, u kojem se plin dobijen u koraku b prvo hladi, čime se dio plina kondenzira, a onda se razdvaja na plin bogat ugljičnim dioksidom, koji se poslije toga hladi u koraku c, i na tekućina koja sadrži apsorbent i ugljični dioksid, koja se reciklira u rektifikacijskoj koloni poslije povećanja temperature i/ili smanjenja tlaka.
The process according to any of the claims 1 to 9, wherein an intermediate stripping step is incorporated between the steps b and c, in which the gas obtained in step b is pressurised before it is used for stripping the liquid of absorbing agent obtained in step f, after which said stripped liquid of absorbing agent is recycled to the stripper column. 
Postupak prema bilo kojem od zahtjeva 1 do 9, pri čemu je između koraka b i c uključen međukorak rektifikacije, u kojem se plin dobijen u koraku b stavlja pod tlak prije no što se uporabi za rektifikaciju tekućine i apsorbenta dobijene u koraku f, poslije čega se spomenuta rektificirana tekućina apsorbenta reciklira u rektifikacijskoj koloni.
The process according to claim 13, wherein said intermediate stripping step is performed one, two, three, four, five or six times by counter-currently bringing the liquid of absorbing agent obtained in step f in contact with the gas obtained in step b in a stripper unit, which comprises one, two, three, four, five or six consecutively connected stripper column(s). 
Postupak prema zahtjevu 13, pri čemu se spomenuti međukorak rektifikacije izvodi jedan, dva, tri, četiri, pet ili šest puta suprotnosmjernim dovođenjem tekućine apsorbenta dobijene u koraku f u kontakt sa plinom dobijenim u koraku b u rektifikacijskoj jedinici, koja sadrži jednu, dvije, tri, četiri, pet ili šest uzastopno povezanih rektifikacijskih kolona.
The process according to any of the claims 1 to 15, wherein the process is a process for boosting hydrogen production. 
Postupak prema bilo kojem od zahtjeva 1 do 15, pri čemu taj postupak je postupak poboljšanje proizvodnje vodika.